Work

Insomnia and medication overuse headache: neurobiological links, reciprocal interactions, and integrated therapeutic strategies

Year: 2026

Type: review

Abstract: Medication overuse headache (MOH) and insomnia are not merely coincidental companions: each measurably worsens the severity and treatment response of the other. Whether this association reflects a genuine reciprocal influence, a shared constitutional vulnerability, or some combination of both carries direct practical consequences for clinical decision-making. This narrative review synthesizes evidence from Mendelian randomization genetics, polysomnographic cohort studies, pharmacological withdrawal trials, and mechanistic neurobiology, based on a search of PubMed, Embase, and Google Scholar through 20 June 2026. Genetic analyses are compatible with a directional association between insomnia liability and migraine risk, although causation is not established and the instruments capture migraine broadly rather than the MOH phenotype, a limitation that applies to all causal inferences in this review. In the other direction, opioids, barbiturates, and triptans each disrupt sleep architecture through mechanisms specific to their molecular targets, and questionnaire-based withdrawal studies consistently report parallel improvements in sleep quality and headache frequency. Three neurobiological substrates appear centrally involved: orexinergic dysregulation, melatonin suppression, and glial neuroinflammation. Together, they may sustain a self-reinforcing cycle that neither detoxification alone nor sleep treatment alone can fully dismantle. The COMISA phenotype (comorbid insomnia and obstructive sleep apnea) and concurrent psychiatric illness compound treatment resistance and raise relapse rates at one year. Objective polysomnographic evidence that sleep architecture actually recovers after drug withdrawal is absent from the literature - a gap that limits the mechanistic conclusions that can be drawn. The available evidence is consistent with the hypothesis that concurrent medication withdrawal, CBT-I, preventive pharmacotherapy - including anti-CGRP monoclonal antibodies - and CPAP where indicated may yield better outcomes than sequential management, but this hypothesis has not been tested in a randomized controlled trial. Designing that trial is the most pressing research need in this field.

Source: Frontiers in Pain Research

DOI: 10.3389/fpain.2026.1911261